Implications of KRAS mutations in acquired resistance to treatment in NSCLC.

about

[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].

P2860

Q54109659-2B5DA7A8-7701-4963-873E-E483D92820D0

P2860

Implications of KRAS mutations in acquired resistance to treatment in NSCLC.

Item

http://www.wikidata.org/entity/Q49787333

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Implications of KRAS mutations in acquired resistance to treatment in NSCLC.

@en

Implications of KRAS mutations in acquired resistance to treatment in NSCLC.

@nl

type

Item

label

Implications of KRAS mutations in acquired resistance to treatment in NSCLC.

@en

Implications of KRAS mutations in acquired resistance to treatment in NSCLC.

@nl

prefLabel

Implications of KRAS mutations in acquired resistance to treatment in NSCLC.

@en

Implications of KRAS mutations in acquired resistance to treatment in NSCLC.

@nl

P1476

Implications of KRAS mutations in acquired resistance to treatment in NSCLC

@en

P2093

Elena Arrigoni

http://www.w3.org/2001/XMLSchema#string

Eleonora Rofi

http://www.w3.org/2001/XMLSchema#string

Giuliana Restante

http://www.w3.org/2001/XMLSchema#string

Massimo Di Maio

http://www.w3.org/2001/XMLSchema#string

Romano Danesi

http://www.w3.org/2001/XMLSchema#string

Stefania Crucitta

http://www.w3.org/2001/XMLSchema#string

Stefano Fogli

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

KRAS oncogene in lung cancer: focus on molecularly driven clinical trials

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

The blockade of immune checkpoints in cancer immunotherapy

P304

6630-6643

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.23553

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Iacopo Petrini

Marzia Del Re

P577

2017-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29464099

http://www.w3.org/2001/XMLSchema#string

P932

5814239

http://www.w3.org/2001/XMLSchema#string

Implications of KRAS mutations in acquired resistance to treatment in NSCLC.

about

P2860

P2860

Implications of KRAS mutations in acquired resistance to treatment in NSCLC.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932